BeiGene, Ltd.
06160
2022 12 31
2022 12 31 2021
2022 12 31 2021 12 31
239.6 20.4% 14 2021 12 31
620.6 97.9% 1,254.6
2021 12 31 381.0 161.3
2022 12 31 2021 12 31
590.6 22.6% 3,205.6
2022 12 31 2021 12 31
546.0 37.5% 2,003.8
2022 12 31 1.49
2021 12 31 1.21 23.1%
1
12 31
2022 2021
3,869,564 4,375,678
5 196 328
6 665,251 2,241,962
7 173,168 483,113
8 282,346 242,626
14 216,553 270,173
5,207,078 7,613,880
5 5,277 6,881
11 845,946 587,605
10 109,960 117,431
12 40,616 46,679
14 170,413 163,049
1,172,212 921,645
6,379,290 8,535,525
15 294,781 262,400
14 467,352 558,055
4 213,861 187,414
13 25,189 21,395
10 24,041 21,925
4 114,335 120,801
16 328,969 427,565
1,468,528 1,599,555
2
12 31
2022 2021
16 209,148 202,113
4 42,026 220,289
10 34,517 43,041
13 15,996 14,169
4 179,625 269,561
14 46,095 54,234
527,407 803,407
1,995,935 2,402,962
25
0.0001
9,500,000,000 2022 12 31
2021 12 31
1,356,140,180 1,334,804,281 135 133
11,540,979 11,191,007
21 (77,417) 17,950
(7,080,342) (5,076,527)
4,383,355 6,132,563
6,379,290 8,535,525
3
12 31
2022 2021
17 1,254,612 633,987
4 161,309 542,296
1,415,921 1,176,283
286,475 164,906
1,640,508 1,459,239
1,277,852 990,123
12 751 750
3,205,586 2,615,018
(1,789,665) (1,438,735)
52,480 (15,757)
6 (223,852) 15,904
(1,961,037) (1,438,588)
13 42,778 19,228
(2,003,815) (1,457,816)
19 (1.49) (1.21)
19 1,340,729,572 1,206,210,049
( )
(19.43) (15.71)
103,133,044 92,785,388
4
12 31
2022 2021
(2,003,815) (1,457,816)
21 (90,421) 13,714
24 365 1,865
21 (5,311) (4,571)
(2,099,182) (1,446,808)
5
12 31
2022 2021
(2,003,815) (1,457,816)
66,278 46,457
20 303,162 240,712
4 68,665 83,500
4 (96,402) (112,486)
6 21,996 (7,632)
2,059 3,377
9,047 23,510
304,112 (423,019)
(56,689) (153,333)
(3,282) (107,128)
(4,352) 20,008
45,627 140,044
(151,816) 407,703
(1,209) (2,620)
(1,496,619) (1,298,723)
(325,434) (262,942)
(1,485) (2,147,881)
1,563,618 3,146,891
(143,665) (8,500)
12 – (43,409)
6 (15,911) (43,500)
1,077,123 640,659
6
12 31
2022 2021
22 – 3,392,616
22 – 50,000
16 37,372 16,838
16 313,774 406,449
16 (417,081) (321,754)
46,964 92,762
(18,971) 3,636,911
(69,383) 14,035
(507,850) 2,992,882
4,382,887 1,390,005
3,875,037 4,382,887
3,869,564 4,375,678
196 328
5,277 6,881
29,500 15,695
25,169 29,967
95,346 53,197
– 75,000
7
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,618,711) 3,803,281
115,055,260 12 3,392,604 – – 3,392,616
2,151,877 – 50,000 – – 50,000
28,778,893 3 92,759 – – 92,762
(2,003,690) – – – – –
– – 240,712 – – 240,712
– – – 11,008 – 11,008
– – – – (1,457,816) (1,457,816)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (5,076,527) 6,132,563
– – (152) – – (152)
1,375,621 – – – – –
19,960,278 2 46,962 – – 46,964
– – 303,162 – – 303,162
– – – (95,367) – (95,367)
– – – – (2,003,815) (2,003,815)
2022 12 31 1,356,140,180 135 11,540,979 (77,417) (7,080,342) 4,383,355
8
1.
3
(BTK)
PD-1
PARP1 PARP2
13
2,700
50 80
30
3 18,000
CMOs
2010
29 9,000
9
2022 12 31 48
BeiGene 101 – 100%
BeiGene AUS Pty Ltd BeiGene Australia 56,947,230 100%
BeiGene Austria GmbH 35,000 100%
* 1,922,787,023 100%
* 14,540,000,000 100%
BeiGene (Canada) ULC 100 100%
BeiGene ESP, S.L.U. 3,000 100%
BeiGene France Sarl 7,500 100%
* 12,490,389,800 100%
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
BeiGene (Hong Kong) Co., Limited 1 100%
13,700,000,000
* 4,000,000 100%
BeiGene International GmbH 20,000 100%
BeiGene (Italy) S.r.l. 10,000 100%
BeiGene Brazil Ltda. 2,450,190 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene South Africa Pty Ltd. – 100%
BeiGene Sweden AB 25,000 100%
BeiGene Turkey Medical Products Trade Limited Company 10,000 100%
BeiGene Ireland Limited BeiGene Ireland – 100%
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 145,000,000 100%
BeiGene Netherlands B.V. – 100%
BeiGene NZ Unlimited BeiGene NZ, Limited 100,000 100%
10
BeiGene Pharmaceuticals GmbH 20,000 100%
* 3,800,000 100%
BeiGene Pharmaceuticals Israel Ltd. 10,000 100%
* 7,000,000 100%
* 1,000,000 100%
* 1,434,344,311 100%
* 1,000,000 100%
* 270,000,000 100%
BeiGene Singapore Pte., Ltd. 1 100%
* 3,673,218,389 100%
BeiGene Switzerland GmbH BeiGene Switzerland 20,000 100%
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 143 100%
BeiGene United Kingdom, Ltd. 110 100%
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC 54,000,000 100% .
BeiGene US Manufacturing Co., Inc. 210,000,000 100%
BeiGene Hopewell Urban Renewal, LLC 125,000,000 100% .
Pi Health, Ltd. 22,500,000 100%
Pi Health USA, LLC 5,000,000 100%
Pi Health Brasil Consultoria Ltda. – 100%
B10 Health Technologies Private Limited 370,344,475 100%
Newco 101 – 100%
*
11
2.
2020
MapKure, LLC MapKure
2020 6 MapKure
6 2020 11
9
740
2022
2022 10 2022 9 30
12
99 108
2022 12 31 12
2021
3 13 19
2021 11 2021-10 832
2021 12 15
2022
1 1
13
3.
2
2021 2
2021 12 31
110,424 (110,424) –
1,032,069 (110,424) 921,645
8,645,949 (110,424) 8,535,525
(4,966,103) (110,424) (5,076,527)
6,242,987 (110,424) 6,132,563
8,645,949 (110,424) 8,535,525
2021 12 31
(25,234) 44,462 19,228
(1,413,354) (44,462) (1,457,816)
(1.17) (0.04) (1.21)
(15.23) (0.48) (15.71)
2021 12 31
(1,413,354) (44,462) (1,457,816)
(1,402,346) (44,462) (1,446,808)
14
2021 12 31
(1,413,354) (44,462) (1,457,816)
(41,085) 44,462 3,377
(1,298,723) – (1,298,723)
2020 12 31 (3,552,749) (65,962) (3,618,711) 3,869,243 (65,962) 3,803,281
(1,413,354) (44,462) (1,457,816) (1,413,354) (44,462) (1,457,816)
2021 12 31 (4,966,103) (110,424) (5,076,527) 6,242,987 (110,424) 6,132,563
4.
2022 2021 12 31
2022 2021 12 31
12 31
2022 2021
– 484,646
46,822 53,671
104,994 3,979
9,493 –
161,309 542,296
15
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2) (3)
606
650,000,000
484,646,000 165,354,000
16
2021 12 31
2021 12 31
2022
2021 12 31 39,655,000 53,421,000
2022 12 31
9,493,000
2021 12
TIGIT
5
2022
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000
1,150,000,000
50%
25%
606
(1)
(2)
(3) (4)
17
300,000,000
71,980,000
213,450,000
14,570,000
2022
2021 12 31
104,994,000 3,979,000 2022 2021 12 31
7,167,000 250,000
2019 10
2020 1 2
XGEVA 2019 2020 11
2020 7
2020 12
B
2021 7
(R/R) 2022 4
CD19 B
18
1,250,000,000
K R A S G12C
LUMAKRAS(sotorasib) AMG 510
AMG 510
HGRAC 2020 2022
AMG510
AMG 510
2023 2 (i) 2023 1 1 2023 8 31
AMG 510 (ii) AMG 510
808
100%
2019 10 31
2020 1 2 174.85
15,895,001 20.5%
Anthony Hooper
2020 1 2023 1
2022 4 20
132.74 2,109,902,000
601,857,000
2,779,241,000 2,162,407,000
616,834,000
19
2022 2021 12 31
12 31
2022 2021
98,955 115,464
96,402 112,486
195,357 227,950
2022
12 31
595,702
2022 12 31 2021 12 31
12 31
2022 2021
114,335 120,801
179,625 269,561
293,960 390,362
2022 2021 12 31
12 31
2022 2021
5,898 1,893
(54,865) (45,152)
(1,216) 423
(50,183) (42,836)
2022 2021 12 31
71,720,000 110,303,000 2022 12 31 2021
12 31 54,064,000 106,790,000
20
2022 2021 12 31
12 31
2022 2021
68,665 83,500
5,500 15,000
– 43,394
74,165 141,894
2022 12
LY01005 2022 12 48,665,000
30,000,000
Shoreline Biosciences, Inc.
2021 6 Shoreline Biosciences Inc. Shoreline
Shoreline iPSC
Shoreline
Shoreline
Shoreline
Shoreline 2022 1 45,000,000
2021 12
31
2021 12
LBL-007 LAG-3
2022 1
30,000,000 742,000,000
2021 12 31
21
EUSA Pharma
2020 1 EUSA Pharma EUSA
β
EUSA
EUSA 40,000,000
120,000,000
2020 12 31 2021
EUSA
Assembly Biosciences, Inc.
2020 7 Assembly Biosciences, Inc Assembly Assembly
Assembly ABI-H0731 ABI-H2158
ABI-H3733
Assembly
Assembly 40,000,000
503,750,000 Assembly
2020
12 31
2020 8
(BAT1706)
2020 9 10
2020 9 18
2020 10 20,000,000
145,000,000
2020 12 31 2021 11
22
2022 2021 12 31
5.
2022 12 31 2021 12 31 5,473,000
7,209,000
6.
2022 12 31
674,262 – 9,011 665,251
674,262 – 9,011 665,251
23
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
2022 12 31 2022 12
31
2022 12 31
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap
Leap 2021 9 Leap
7,250,000 Leap 2022 12 31
Leap 7.4%
11.7%
2022 2021 12 31
30,102,000 9,386,000
2022 12 31 2021 12 31
12 31
2022 2021
Leap 3,307 23,809
Leap 706 10,306
2022 12 31 2021 12 31
57,054,000 43,722,000
2022 12 31
5,065,000 2021
12 31
24
2022 12 31 2021 12 31
27,710,000 22,955,000
2022 2021 12 31
3,682,000 1,796,000
7.
12 31
2022 2021
173,379 483,528
(211) (415)
173,168 483,113
30 120
12 31
2022 2021
6 172,633 483,113
6 12 535 –
173,168 483,113
12 31
2022 2021
1 1 415 112
(219) 309
1 –
14 (6)
12 31 211 415
25
8.
12 31
2022 2021
88,957 78,140
20,886 9,397
172,503 155,089
282,346 242,626
9.
(CTA) (MAA)
2017 3
200,000,000
95%
100,000,000 5%
2017 3 7
900,000,000 2019 9
100%
95%
2020 9
5% 28,723,000 195,262,000
2020 11
9,116,000
100% 19,599,000
132,061,000 900,000,000 36,558,000 249,140,000
26
200,000,000
120,000,000
80,000,000
2020 10 80,000,000
118,320,000 2021 10 9
198,320,000 200,000,000
73,640,000 500,000,000
14,728,000 100,000,000
58,912,000 400,000,000
2021 12 31 15,693,000 100,000,000
2022 11 16
10.
50 36 30
12
12 31
2022 2021
25,938 22,536
6,834 4,892
1,299 1,823
34,071 29,251
12 31
2022 2021
56,008 60,762
53,952 56,669
109,960 117,431
24,041 21,925
34,517 43,041
58,558 64,966
27
2023 12 31 26,278
2024 12 31 21,647
2025 12 31 11,312
2026 12 31 2,821
2027 12 31 966
63,024
(4,466)
58,558
12 31
2022 2021
28,064 19,962
22,278 37,454
12 31
2022 2021
3 3
5.76% 5.15%
11.
12 31
2022 2021
65,485 65,485
158,908 118,203
53,786 50,288
222,448 144,083
175,679 119,585
47,483 27,404
723,789 525,048
(171,470) (124,286)
293,627 186,843
845,946 587,605
2021 11 75,197,000 42
28
2022 12 31 2021 12 31
12 31
2022 2021
224,392 90,229
33,332 63,361
12,256 17,178
23,647 16,075
293,627 186,843
2022 2021 12 31 62,302,000 44,742,000
12.
2022 12 31 2021 12 31
2022 12 31 2021 12 31
7,500 (4,000) 3,500 7,500 (3,250) 4,250
41,235 (4,119) 37,116 43,394 (965) 42,429
816 (816) – 816 (816) –
49,551 (8,935) 40,616 51,710 (5,031) 46,679
10
2018 9
2020 2
2024 2
12
12 31
2022 2021
3,225 965
751 750
3,976 1,715
29
2022 12 31
12 31
2023 3,170 750 3,920
2024 3,170 750 3,920
2025 3,170 750 3,920
2026 3,170 750 3,920
2027 3,170 500 3,670
2028 21,266 – 21,266
37,116 3,500 40,616
13.
12 31
2022 2021
(583,610) (606,752)
67,744 34,923
(1,445,171) (866,759)
(1,961,037) (1,438,588)
12 31
2022 2021
27,905 15,252
4,844 (9)
6,547 805
39,296 16,048
3,480 4,919
– (35)
2 (1,704)
3,482 3,180
42,778 19,228
30
12 31
2022 2021
(1,961,037) (1,438,588)
25% 25%
(490,259) (359,647)
288,133 185,874
30,598 (2,826)
33,872 (27,411)
229,550 254,768
(49,116) (31,530)
42,778 19,228
(2.2)% (1.3)%
12 31
2022 2021
97,896 84,766
862,214 625,114
19,700 14,982
86,000 82,060
798,563 937,069
10,348 11,571
63,156 –
(10,098) (11,322)
1,927,779 1,744,240
(1,943,775) (1,758,409)
(15,996) (14,169)
2022 12 31
2022 2021 12 31
229,550,000 254,768,000
31
2022 2021 12 31 5,077,247,000
3,644,981,000 2022 12 31 2024
2032 1,633,101,000 2025 2029
3,397,529,000 26,079,000
108,861,000 2036 2042
2022 2021 12 31
12 31
2022 2021
1 1 9,925 7,123
– –
– –
1,630 2,802
– –
12 31 11,555 9,925
2022 12 31 12
2022 2021
12 31
2022 12 31 2013 2022
2012 2022 2018 2022
2015 2022
2012 2022
2025
2022 12 31 3,894,000
0.01
2022 12 31
2,379,000
32
14.
12 31
2022 2021
71,488 87,239
20,478 58,579
22,777 12,010
3,039 5,052
3,664 1,695
58,950 78,538
1,510 2,982
34,647 24,078
216,553 270,173
12 31
2022 2021
109 109
22,025 14,140
(1)
48,642 24,237
804 17,162
7,054 6,609
91,779 100,792
170,413 163,049
(1)
33
12 31
2022 2021
184,775 139,966
139,168 213,922
51,806 71,560
18,815 45,661
41,817 59,639
30,971 27,307
467,352 558,055
12 31
2022 2021
38,176 46,352
7,760 7,814
159 68
46,095 54,234
15.
12 31
2022 2021
3 290,284 257,977
3 6 2,570 3,210
6 1 1,379 1,110
1 548 103
294,781 262,400
34
16.
2022 12 31 2021 12 31
12 31
2022 2021
2018 4 4 580,000 9 2027 4 4 (1) 7,250 50,000 1,255 8,000
2020 1 22 (2) 9 2029 1 20 (2) 1,450 10,000 1,569 10,000
2020 11 9 378,000 9 2029 11 8 (3) 5,437 37,500 – –
2020 9 24 200,000 (4) 4.3% 150,000 1,034,554 200,000 1,274,535
2020 9 24 500,000 (5) 4.5% – – 15,693 100,000
2022 2 25 50,000 1 2023 2 25 2.2% 50,000 344,851 – –
(6) 114,832 792,000 209,048 1,332,197
328,969 2,268,905 427,565 2,724,732
2018 4 4 580,000 9 2027 4 4 (1) 75,395 520,000 89,444 570,000
2020 1 22 (2) 9 2029 1 20 (2) 49,369 340,500 53,353 340,000
2020 11 9 378,000 9 2029 11 8 (3) 47,847 330,000 59,316 378,000
2022 7 29 480,000 10 2032 7 28 (7) 36,537 252,000 – –
209,148 1,442,500 202,113 1,288,000
1. 2022 12 31
4.7% 2022 12 31 1,171,000
8,000,000
2. 2020 1 22
1,100,000,000
2020 12 31
1,100,000,000 350,000,000 2022 12 31
4.4% 2022 12 31 1,484,000
10,000,000 2017 3 3
3. 2022 12 31
4.0%
4. 2020 9 200,000,000
120,000,000 80,000,000
2021 10 8
2021 10 8 2022 10 8
2022 9 30
2022 10 10 200,000,000
150,000,000
35
5. 2020 9 73,640,000
500,000,000 14,728,000 100,000,000
58,912,000 400,000,000
(i)2021 11 9
(ii) 2021 10 8
(i)2022 11 9
(ii)
2022 10 10 13,980,000 100,000,000
Hillhouse Capital Hillhouse
Capital Hillhouse Capital
6. 2022 12 31
2,435,000,000 2021 1 19
2023 9 18 2022 12 31 113,774,000
792,000,000 2022 12 31 200,446,000
1,332,197,000 2022 12 31
2.6%
7. 2022 7
480,000,000 2022
12 31 4.2%
2022 12 31 37,372,000
252,000,000
2022 12 31
2023 12 31 328,969
2024 12 31 29,412
2025 12 31 35,136
2026 12 31 44,697
2027 12 31 44,697
55,206
538,117
2022
2021 12 31 21,699,000 29,263,000
2,594,000 1,054,000
17.
36
2022 2021 12 31
12 31
2022 2021
1,438,440 748,824
(183,828) (114,837)
1,254,612 633,987
2022 2021 12 31
12 31
2022 2021
564,651 217,987
422,885 255,119
79,049 70,065
63,398 45,956
38,124 1,353
36,107 12,515
13,696 –
15,213 19,591
5,460 3,661
16,029 7,740
1,254,612 633,987
2022 2021 12 31
12 31
2022 2021
1 1 59,639 11,874
183,828 114,837
(201,650) (67,072)
12 31 41,817 59,639
37
18.
12 31
2022 2021
286,475 164,906
11 62,302 44,742
1,640,508 1,459,239
10 25,938 22,536
12 3,976 1,715
1,000,890 720,551
303,162 240,712
50,358 38,810
1,354,410 1,000,073
233,812 5,991
(74,234) (13,528)
44 106
2022 2021 12 31 602,585,000 463,441,000
19.
12 31
2022 2021
(2,003,815) (1,457,816)
1,340,729,572 1,206,210,049
(1.49) (1.21)
2022 2021 12 31
2022
2021 12 31
38
20.
2016
2016 1 2016
2016 2016 2 65,029,595
2016 2011 2011
2016 2011
2022 12 31
2011 2016 5,166,653 2016
2017 1 1 (i)
(5)% (ii)
2018 1 1 29,603,616
2016 2018 8
2016
2018 12 2016
38,553,159
2020 6 2016 57,200,000
2030 4 13 2016
2022 12 31 2016 75,034,504
2016 2016
2016 66,300,000
2022 3 31 5% 2022 6 22
2018
2018 6 2018 2018
12,000,000
5635(c)(4)
5635(c)(4) 2018
2018
2016 2018 8
2018
2016 2018 2022 6 22
39
2018
2018 6 2018
3,500,000 2018 8
2018 12
3,855,315 7,355,315
6
15%
10%
1 2
2022 8 31 861,315 171.66 13.20 145.91 11.22 9,667
2022 2 28 667,160 210.52 16.19 178.94 13.76 9,183
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
2020 8 31 485,069 164.06 12.62 139.45 10.73 5,203
2020 2 28 425,425 145.54 11.20 123.71 9.52 4,048
1
2
2022 12 31 3,666,071
10
40
2011 2016 2018
2020 12 31 84,991,715 5.27
6,244,524 26.46 12.40
(17,233,853) 4.52 367,110
(1,797,498) 13.27
2021 12 31 72,204,888 7.08
12,516,816 12.34 6.40
(5,898,217) 4.63 52,258
(2,296,634) 16.46
2022 12 31 76,526,853 7.85 5.33 745,340,712
2022 12 31 58,017,219 5.67 4.2 673,364,735
2022 12 31 73,842,956 7.60 5.2 734,904,195
2022 12 31 15,825,737
88,859,000 2.4
2022 2021 12 31
62,548,000 53,571,000
41
12 31
2022 2021
5.51 ~ 9.04 9.94 ~ 14.97
1.8% ~ 3.9% 1.1% ~ 1.7%
2.8 2.8
51% ~ 60% 51% ~ 59%
0% 0%
10 10
2022 2021 12 31
2022 12 31
2016 2018
2020 12 31 34,876,972 12.50
17,173,767 25.58
(10,703,381) 12.23
(5,264,376) 15.82
2021 12 31 36,082,982 18.33
38,707,669 12.46
(12,533,586) 16.37
(6,859,892) 16.72
2022 12 31 55,397,173 14.87
2022 12 31 47,392,282 14.87
2 0 2 2 12 31
580,815,000 2.9
42
2022 2021 12 31
12 31
2022 2021
139,348 114,357
163,814 126,355
303,162 240,712
21.
2020 12 31 14,184 871 (8,113) 6,942
13,714 (4,504) 309 9,519
(1)
– (67) 1,556 1,489
13,714 (4,571) 1,865 11,008
2021 12 31 27,898 (3,700) (6,248) 17,950
(90,421) (5,311) (446) (96,178)
(1)
– – 811 811
(90,421) (5,311) 365 (95,367)
2022 12 31 (62,523) (9,011) (5,883) (77,417)
(1)
43
22.
2022 2021 12 31
2019 10 31 2019 12 6 2020 9 24
(SPA) 2021 9
165,529 2,151,877
50,000,000
2021 12
192.60
391.68 115,055,260
3,392,616,000
44
23.
10%
50%
2022 2021 12 31
10%
2022 12 31 2021 12 31
3,548,881,000 760,476,000
45
24.
2022 2021 12 31
83,860,000 63,772,000
401(k) 401(k) 401(k)
401(k) 2021 4%
2022 12 31 2021 12 31 401(k)
10,298,000 7,483,000
2022 2021 12 31
3,887,000 2,986,000
2022 12 31
2021 12 31 45,835,000 34,517,000
38,075,000 26,703,000
14
2023 2,553,000
2022
12 31
2023 68
2024 545
2025 442
2026 260
2027 755
2028 – 2032 7,185
9,255
46
25.
2022 12 31 117,293,000 55,346,000
61,947,000 BMS
BMS
2022 12 31 404,914,000
1,250,000,000
2022 12 31 595,702,000
2022 12 31 22,327,000
19,000,000 2022 12 31
16,000,000
(CRO)
47
26.
12 31
2022 2021
840,032 517,173
502,626 495,265
73,263 163,845
1,415,921 1,176,283
2022 12 31 2022 12
31 112,916,000
389,710,000
2021 12 31 379,607,000
115,658,000 2022 12 31
48,393,000 24,870,000 2021 12 31
2
2021 2022
2021
3 31 6 30 9 30 12 31
2022
306,626 341,572 387,628 380,095
(443,287) (439,399) (438,357) (468,622)
(435,198) (565,726) (557,556) (445,335)
(435,198) (565,726) (557,556) (445,335)
(0.33) (0.42) (0.41) (0.33)
48
3 31 6 30 9 30 12 31
2021
605,872 149,992 206,440 213,979
70,167 (474,838) (462,325) (571,739)
55,580 (484,604) (438,114) (590,678)
55,580 (484,604) (438,114) (590,678)
0.05 (0.41) (0.36) (0.48)
0.04 (0.41) (0.36) (0.48)
27.
2022 12 31
(i) (iii) (iv)
(1,640,508) (14,697) – 471 (1,654,734)
(1,277,852) (19,296) – 366 (1,296,782)
) 52,480 – – (3,142) 49,338
(1,961,037) (33,993) – (2,305) (1,997,335)
(42,778) – 10,311 – (32,467)
(2,003,815) (33,993) 10,311 (2,305) (2,029,802)
49
2021 12 31
(i) (iii)
(1,459,239) (21,541) – (1,480,780)
(990,123) (27,189) – (1,017,312)
(1,438,588) (48,730) – (1,487,318)
(19,228) 5,253 (11,775) (25,750)
(1,457,816) (43,477) (11,775) (1,513,068)
2022 12 31
(i) (iii) (ii) (iv)
109,960 – – (2,305) 107,655
6,379,290 – – (2,305) 6,376,985
11,540,979 33,993 – – 12,056,915
174,049* 307,894* –
(7,080,342) (33,993) – (2,305) (7,598,583)
10,311 – –
(184,360)* (307,894)* –
4,383,355 – – (2,305) 4,381,050
50
2021 12 31
(i) (ii) (iii)
– 5,253 – 110,424 125,744
10,067* – –
8,535,525 15,320 – 110,424 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(5,076,527) (48,730) – (11,775) (5,568,781)
5,253 (307,894)* (13,856)*
(115,252)* – –
6,132,563 15,320 – 110,424 6,258,307
*
(i)
2022 12 31
33,993,000
2021 48,730,000 2021
5,253,000
51
(ii)
2016 2
307,894,000
307,894,000
(iii)
2022 12 31
110,424,000
2022 12 31
10,311,000
52
(iv)
2019 1 1
16
(v)
9
2022 12 31 2022 12 31
28.
2022 12 31 2021 12
31
53
3
(BTK)
PD-1
PARP1 PARP2
13
2,700
50 80
30
3
18,000
CMO
2010
29 9,000
54
2023 2 24 (NMPA)
PD-L1
(G/GEJ)
2023 1 19 (FDA)
(CLL)
(SLL)
2023 1 19 (MHRA)
CLL CD20
(MZL)
2023 1 18 PD-1
2022
RANKL
2023 3 1
2022 12 30 (NMPA)
(CDE)
(HCC)
(sBLA)
2022 11 17 (EC)
(TN)
(R/R)CLL
2022 11 10
(WM) CD20 (R/R)MZL
55
12
1.
950
14
3
(CLL) (PFS) (ORR)
BCL-2 BGB-11417 HPK1 BGB-15025
BTK (CDAC) BGB-16673
OX40 LAG-3 TIM-3
CDAC ADC CAR-
NK mRNA
2. 2,300
(CRO)
75%
56
3.
29
35 4,800
800 ALPINE
BTK
2022 (ASH)
BCL-2
PD-1
PD-1/PDL-1
OX40
TIGIT LAG-3 TIM-3
4. 3,500
BTK
PD-1/PDL-1
13
65
5.
2023
57
2021 1
(1)
(2)
58
2021 12
TIGIT
5
(1)
(2)
(3)
59
(CROs) CMOs
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
BGB-10188 PI3Kδ
60
BGB-23339 2(TYK2)
LBL-007 LAG-3
Mirati Therapeutics, Inc. Mirati
ZW25(Zanidatamab) ZW49 Zymeworks Inc. Zymeworks
HER2
(BAT1706)
61
62
2021 12
2022 2021 12 31
2022 2021 12 31
12 31
2022 2021 %
1,254,612 633,987 620,625 97.9%
161,309 542,296 (380,987) (70.3)%
1,415,921 1,176,283 239,638 20.4%
286,475 164,906 121,569 73.7%
1,640,508 1,459,239 181,269 12.4%
1,277,852 990,123 287,729 29.1%
751 750 1 0.1%
3,205,586 2,615,018 590,568 22.6%
(1,789,665) (1,438,735) (350,930) 24.4%
52,480 (15,757) 68,237 (433.1)%
(223,852) 15,904 (239,756) (1,507.5)%
(1,961,037) (1,438,588) (522,449) 36.3%
42,778 19,228 23,550 122.5%
(2,003,815) (1,457,816) (545,999) 37.5%
63
2021 12 31 12 2022 12 31
2.396 14
6.50
2022 2021 12 31
12 31
2022 2021 %
1,254,612 633,987 620,625 97.9%
– 484,646 (484,646) (100.0)%
46,822 53,671 (6,849) (12.8)%
104,994 3,979 101,015 2,538.7%
9,493 – 9,493
161,309 542,296 (380,987) (70.3)%
1,415,921 1,176,283 239,638 20.4%
12 31
2022 2021 %
564,651 217,987 346,664 159.0%
422,885 255,119 167,766 65.8%
79,049 70,065 8,984 12.8%
63,398 45,956 17,442 38.0%
38,124 1,353 36,771 2,717.7%
36,107 12,515 23,592 188.5%
15,213 19,591 (4,378) (22.3)%
13,696 – 13,696
5,460 3,661 1,799 49.1%
16,029 7,740 8,289 107.1%
1,254,612 633,987 620,625 97.9%
64
2022 12 31 13 6.34
2021 8
2022
(NRDL)
NRDL
2022 12 31
5.647
159.0% 2022 12 31
3.897
1.157 237.0% MCL WM MZL
2022 12 31
1.503 48.6% CLL SLL
2022 12 31
4.229
65.8% 2022 12 31
2021 3 2022 1 NRDL
2021
4,560
2021 12 31 5,750
2021 3 1
NRDL
2022
1 1 NRDL NRDL
2021 12 31
NRDL
NRDL
2022 12 31 1.613
2022 12 31
4,680
1.05
950 2021 12 31 5.423
4.846
2021 12 31
5,370
400
4
65
2021 12 31 1.649 2022 12 31
2.865
2021 8
2021 12 31 4.691
2022 12 31 9.681
74.0% 2022 12 31
77.2%
2021 12 31 15 1.813 12.4%
2022 12 31 16 2022 2021
12 31
12 31
2022 2021 %
469,497 477,761 (8,264) (1.7)%
68,665 83,500 (14,835) (17.8)%
1
98,955 115,464 (16,509) (14.3)%
637,117 676,725 (39,608) (5.9)%
1,003,391 782,514 220,877 28.2%
1,640,508 1,459,239 181,269 12.4%
1. 2022 12 31 1.954
9,900 9,640
2022 12 31
CRO
66
2.209 28.2% 10
1.147
5,760
4,760
2,500
2,400
2021 12 31 9.901 2.877
29.1% 2022 12 31 12.779
1.764
4,600
3,750
2,780
67
2021 12 31 1,580
6,820 433.1% 2022 12 31 5,250
2021
2021 12 31 1,590
2.398 2022 12 31 2.239 2022 12
31
2022 12 31 4,280 2021 12 31
1,920 2022 12 31
2017 (IRC) 174
2022 1 1
68
2022 12 31
(1) 17 (2) 190
28 (3) 44.8
2021 12 31 483.1 64.2% 2022 12
31 173.2 3.0
2021 12 31 242.6 16.4% 2022 12 31
282.3
2021 12 31 270.2 19.8%
2022 12 31 216.6 (1)
(2) (3)
69
2021 12 31 587.6 44.0% 2022 12
31 845.9
2022 12 31 2021 12 31
294.8 262.4
12 31
2022 2021
3 290,284 257,977
3 6 2,570 3,210
6 1 1,379 1,110
1 548 103
294,781 262,400
2022 12 31 2021 12 31
12 31
2022 2021
184,775 139,966
139,168 213,922
51,806 71,560
18,815 45,661
41,817 59,639
30,971 27,307
467,352 558,055
70
2021 12 31 558.1 16.3%
2022 12 31 467.4 (i)
(ii)
2022 12 31
12 31
2022 2021
3,875,037 4,382,887
665,251 2,241,962
538,117 629,678
2022 2021 12 31 20
15 2022 12 31 71
2017 9
2022 12 31
12
2021 12 15
192.60
391.68 115,055,260
34
71
2021 1
6.5
2021 12
TIGIT
2022
1 3
2022 2021 12 31
12 31
2022 2021
4,382,887 1,390,005
(1,496,619) (1,298,723)
1,077,123 640,659
(18,971) 3,636,911
(69,383) 14,035
(507,850) 2,992,882
3,875,037 4,382,887
2022 12 31 15
20 2.239
3.748
1.324
72
2021 12 31 13
15 1.183 2.774
2022 12 31 11 16
3.254 1.437
1,590 150
2021 12 31 6.407
21 2.629 4,340
4,350 850 31
2022 12 31 1,900
4.171 3.138
4,700
3,740
2021 12 31 36 2021
12 34 4.064
9,280
5,000 1,680
3.218
73
2021 12 15
217
SEC
2020 5 SEC
74
2022 12 31
63,024 26,278 36,746
117,293 74,449 42,844
538,117 328,969 209,148
45,947 16,632 29,315
595,702 231,697 364,005
16,000 7,000 9,000
22,327 5,829 16,498
7,760 2,553 5,207
404,914 404,914 –
1,811,084 1,098,321 712,763
2022 12 31 1.173
5,530 BMS
6,190 BMS
3.290 2.091
16
75
12.5
2022 12 31
6
1,900 2022
12 31 1,600
2022 12 31 2,230
2022 12 31
260
2022 12 31 4.049
42 7,520
76
2022 12 31 2021 12 31 39
44 550 720
7 22
2022 12 31
100 2022 12 31
210 210
2022 12 31 2021 12 31 1.732
4.831 2021 12 31
3
77
1994
(PBOC)
2005
2022
2021 12 31 8.2% 2.3%
2022 12 31
78
2022 12 31
2021 12 31 10.3% 12.3%
2022 12 31
2022 12 31
75.2 42
2022 12 31
2022 12 31
2022 12 31 9,000
2021 12 31 8,000
2022 12 31 14
2021 10
2022 12 31 5.5
2021 12 31 7.2
123.9 2021 12 31 145.8
79
2022 12 31 2021 12 31
2022 12 31
2
80
C.2.1
Ranjeev Krishana
3.21
D.3.3 D.3.7
Thomas Malley Corazon (Corsee)
D. Sanders Anthony C. Hooper Thomas
Malley 3.10(2) 3.21
81
3.25
E.1.2
Margaret Han Dugan
Ranjeev Krishana Margaret Han Dugan
2022 6 22
Margaret Han Dugan
2022 9 13
B.3.1
Donald W. Glazer
Michael Goller Alessandro Riva Anthony
C. Hooper Donald W. Glazer
2022 1 31
Alessandro Riva
2022 2 1
82
B.8
83
13.51(B)(1)
13.51(B)(1)
2022 1 31
Margaret Dugan 2022 2 1
2022 2 25
2022 9 13
Alessandro Riva 2022 2 1
2022 11 20
2022 6 22
Corazon (Corsee) D. 2022 11 20
Sanders
84
2020 1 2
174.85 15,895,001
206,635,013
20.5% 2,779,241,000 (a) 2019 10
30 30
36% (b) 1.00 7.84 2019
10 31 26% (c)
2019 10 31 26%
2019 11 29
2022 12 31
2022
12 31
2021 2022
12 31 12 31
(%)
(a)
2,779,241 100.00% 1,869,643 2,080,068 699,173
(a)
12.5
2019 11 29
2026 2019 11 1 2019
12 9 2020 1 3
2020 9 24
20.6%
20.4% 75,000,000
85
90
2020 12 1
(a) 20%
(b) 60 (c)
2020 3 18 2020 9 25
2020 10 9
2021 9
165,529 2,151,877
50,000,000 2022 12 31 50,000,000
2020 7
2020 7 15 2020
202,995,338
2020 7 12 14.2308
185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2022 12 31
86
2021 12 15
2021 6 16 2021
192.60
234.89 391.68
115,055,260
3,392,616,000
(i)
(ii) (iii) (iv)
(v)
2020 11 16 2021 1 29 2021
4 20 2021 5 14 2021 6 1 2021 6 21 2021 6 28
2021 6 30 2021 7 9 2021 7 28 2021 10 15 2021
11 16 2021 11 23 2021 11 24 2021 11 29 2021
11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13
2021 12 21 2021 12 28 2022 4 29 2022 6 27
2022 8 30 2022 9 28 2021 4 30
2022 12 31 83 134
2022 12 31
2022
12 31
2021 2022
12 31 12 31
13,245,940 – 4,499,849 8,746,091
467,700 – 376,601 91,099
150,000 – 153,451 – 3,451*
136,360 – 71,580 64,780
6,000,000 – 2,662,674 3,337,326
1,630,155 – 489,000 1,141,155
21,630,155 – 8,253,155 13,377,000
*
87
Thomas Malley
Anthony C. Hooper Corazon (Corsee) D. Sanders Thomas Malley
Corazon (Corsee) D. Sanders Anthony C. Hooper
Thomas Malley
2022 12 31
2022 12 31
2022 12 31
4400
730 730
2022 12 31
88
2023 6 15
2023 4 17
2023 4
17
183 17
1712-1716
( www.hkexnews.hk) ( www.
beigene.com) 2022 12 31
2023 3 29
Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
89